B. Metzler seel. Sohn & Co. AG Purchases 934 Shares of Insulet Co. (NASDAQ:PODD)

B. Metzler seel. Sohn & Co. AG grew its position in Insulet Co. (NASDAQ:PODD) by 9.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 10,476 shares of the medical instruments supplier’s stock after acquiring an additional 934 shares during the quarter. B. Metzler seel. Sohn & Co. AG’s holdings in Insulet were worth $2,735,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of PODD. O Shaughnessy Asset Management LLC boosted its stake in Insulet by 43.7% during the fourth quarter. O Shaughnessy Asset Management LLC now owns 5,291 shares of the medical instruments supplier’s stock worth $1,381,000 after buying an additional 1,610 shares in the last quarter. IPG Investment Advisors LLC bought a new position in shares of Insulet during the 4th quarter worth about $1,496,000. Arrowstreet Capital Limited Partnership acquired a new stake in shares of Insulet during the 4th quarter valued at about $9,822,000. Allstate Corp bought a new stake in Insulet in the fourth quarter valued at about $545,000. Finally, DnB Asset Management AS raised its position in Insulet by 5.7% in the fourth quarter. DnB Asset Management AS now owns 62,565 shares of the medical instruments supplier’s stock worth $16,334,000 after purchasing an additional 3,370 shares in the last quarter.

Insulet Stock Performance

Insulet stock opened at $263.18 on Wednesday. Insulet Co. has a 1 year low of $160.19 and a 1 year high of $289.46. The company’s 50-day moving average is $271.17 and its two-hundred day moving average is $259.40. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The company has a market cap of $18.48 billion, a PE ratio of 45.45, a PEG ratio of 3.62 and a beta of 1.29.

Insulet (NASDAQ:PODD) last posted its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $1.00 by $0.15. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The company had revenue of $597.50 million for the quarter, compared to the consensus estimate of $582.02 million. Equities analysts anticipate that Insulet Co. will post 3.92 earnings per share for the current year.

Analyst Upgrades and Downgrades

PODD has been the topic of several analyst reports. JPMorgan Chase & Co. upped their price objective on Insulet from $280.00 to $330.00 and gave the company an “overweight” rating in a research note on Thursday, December 12th. Canaccord Genuity Group boosted their price target on Insulet from $304.00 to $324.00 and gave the company a “buy” rating in a research note on Friday, February 21st. StockNews.com lowered Insulet from a “buy” rating to a “hold” rating in a research note on Tuesday, March 4th. Royal Bank of Canada began coverage on shares of Insulet in a research note on Thursday, March 6th. They issued an “outperform” rating and a $340.00 target price on the stock. Finally, Citigroup increased their target price on shares of Insulet from $310.00 to $355.00 and gave the stock a “buy” rating in a research report on Friday, February 21st. Four research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $292.06.

Insider Transactions at Insulet

In other Insulet news, Director Wayne A.I. Frederick sold 1,825 shares of the business’s stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total value of $501,875.00. Following the completion of the transaction, the director now directly owns 3,231 shares of the company’s stock, valued at approximately $888,525. The trade was a 36.10 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Eric Benjamin sold 12,394 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the sale, the executive vice president now directly owns 11,383 shares in the company, valued at approximately $3,187,240. This represents a 52.13 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.47% of the company’s stock.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.